These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35115942)
1. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Xiong L; Zhang H; Guo Y; Song Y; Tao Y Front Pharmacol; 2021; 12():795214. PubMed ID: 35115942 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis. Huang Q; Liao Z; Liu X; Xia Y; Wang J Int Urol Nephrol; 2023 Feb; 55(2):325-334. PubMed ID: 35960479 [TBL] [Abstract][Full Text] [Related]
3. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. Nangaku M; Kondo K; Kokado Y; Ueta K; Kaneko G; Tandai T; Kawaguchi Y; Komatsu Y J Am Soc Nephrol; 2021 Jul; 32(7):1779-1790. PubMed ID: 33883252 [TBL] [Abstract][Full Text] [Related]
8. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858 [TBL] [Abstract][Full Text] [Related]
9. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO Winkelmayer WC; Arnold S; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Parfrey PS Kidney Med; 2023 Jul; 5(7):100666. PubMed ID: 37427293 [TBL] [Abstract][Full Text] [Related]
10. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review. Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836 [TBL] [Abstract][Full Text] [Related]
13. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nangaku M; Farag YMK; deGoma E; Luo W; Vargo D; Khawaja Z Nephrol Dial Transplant; 2020 Jul; ():. PubMed ID: 32719868 [TBL] [Abstract][Full Text] [Related]
14. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225 [TBL] [Abstract][Full Text] [Related]
15. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108 [TBL] [Abstract][Full Text] [Related]
16. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Agarwal R; Anand S; Eckardt KU; Luo W; Parfrey PS; Sarnak MJ; Solinsky CM; Vargo DL; Winkelmayer WC; Chertow GM Am J Nephrol; 2022; 53(10):701-710. PubMed ID: 36450264 [TBL] [Abstract][Full Text] [Related]
17. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non Parfrey PS; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Winkelmayer WC Kidney Med; 2023 Jul; 5(7):100667. PubMed ID: 37427292 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989 [TBL] [Abstract][Full Text] [Related]